Biota, Inc. Announces Royalties from Inavir(R) and Relenza(TM) for Q4 and F2011

MELBOURNE, Australia--(BUSINESS WIRE)--Biota Holdings Limited (ASX:BTA) announces that it has received written notifications from GlaxoSmithKline (GSK) regarding royalties for Relenza™ and from Daiichi Sankyo for Inavir®. Indicative royalties from Relenza™ were $1.8m during the three months ended 30 June 2011. F2011 actual royalties are $6.6m. Royalties from of Inavir® were AUD 160k during the three months ended 30 June 2011, on sales of JPY 390m.